Csetényi J, Gáti E, Hegedüs L, Horváth I P, Holczinger L
Eur J Cancer Clin Oncol. 1985 Jul;21(7):881-5. doi: 10.1016/0277-5379(85)90229-9.
The rate and extent of dibromodulcitol (DBD) conversion by 9000 g rat liver supernatant with an NADPH-generating system (S-9 mix) were studied using 3H-labelled drug. Results indicated that S-9 mix seemed to exert an initial protective effect delaying the solvolysis of DBD for about 30 min at 37 degrees C followed by rapid degradation into exclusively pharmacologically inactive products. Thus S-9 mix contained merely DBD as an effective agent; it amounted to less than 40% of the total radioactive compounds by 120 min. In the control mixtures the sovolytically produced effective drug content, i.e. the sum of DBD, 1,2-anhydro-6-bromo-6-deoxygalactitol (BrEpG), 1,2-5,6-dianhydrogalactitol (DAG) was 63%. Our results suggest the involvement of liver enzymes in the detoxification of DBD into inactive products. Therefore the antitumour effect of DBD cannot be attributed to its active BrEpG and DAG alone. The drug in its unchanged form may contribute to a somewhat greater extent to its cytostatic action than was believed before.
使用3H标记的药物研究了9000g大鼠肝脏上清液与NADPH生成系统(S-9混合物)对二溴卫矛醇(DBD)的转化速率和程度。结果表明,S-9混合物似乎发挥了初始保护作用,在37℃下将DBD的溶剂分解延迟约30分钟,随后迅速降解为完全无药理活性的产物。因此,S-9混合物仅含有DBD作为有效成分;到120分钟时,它占总放射性化合物的比例不到40%。在对照混合物中,溶剂分解产生的有效药物含量,即DBD、1,2-脱水-6-溴-6-脱氧半乳糖醇(BrEpG)、1,2,5,6-二脱水半乳糖醇(DAG)的总和为63%。我们的结果表明肝脏酶参与了将DBD解毒为无活性产物的过程。因此,DBD的抗肿瘤作用不能仅归因于其活性BrEpG和DAG。其未改变形式的药物可能在某种程度上比以前认为的对其细胞抑制作用有更大的贡献。